Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?;Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie?

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 41, 2013, Pages 2084-2088

  Pelzer, U ^a   Sinn, M ^a   Stieler, J ^a   Riess, Hanno ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

heparin; pancreatic cancer; primary prevention; thrombosis

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL DECISION MAKING; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; NUMBERS NEEDED TO TREAT; PANCREAS CANCER; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ADENOCARCINOMA; AMBULATORY CARE; ANTICOAGULANTS; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 84885077223     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1349608     Document Type: Article

References (25)

1. Agnelli G., George D. J., Kakkar A. K. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New Engl J Med: 2012; 366 601 609
2. Agnelli G., Gussoni G., Bianchini C. et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy. Lancet Oncol: 2009; 10 943 949
3. Ay C., Dunkler D., Pirker R. et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica: 2012; 97 1158 1164
4. Ay C., Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thrombosis Res: 2012; 129 01 S6 9
5. Bergqvist D., Agnelli G., Cohen A. T. et al. ENOXACAN II Investigators Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New Engl J Med: 2002; 346 975 980 (Pubitemid 34983247)
6. Cohen A. T., Davidson B. L., Gallus A. S. et al. ARTEMIS Investigators Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients. BMJ: 2006; 332 325 329
7. Debourdeau P., Farge D., Beckers M. et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost: 2013; 11 71 80
8. ENOXACAN Study Group Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery. Brit J Surg: 1997; 84 1099 1103
9. Geerts W. H., Bergqvist D., Pineo G. F. et al. American College of Chest Physicians Prevention of venous thromboembolism. Chest: 2008; 133 06 381S 453S
10. Kakkar A. K., Williamson R. C. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost: 1999; 25 239 243 (Pubitemid 29227152)
11. Khorana A. A., Francis C. W., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thrombosis Haemostasis: 2007; 5 632 634 (Pubitemid 46680709)
12. Khorana A. A., Kuderer N. M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood: 2008; 111 4902 4907
13. Leizorovicz A., Cohen A. T., Turpie A. GG et al. PREVENT Medical Thromboprophylaxis Study Group Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely Ill medical patients. Circulation: 2004; 110 874 879 (Pubitemid 39096017)
14. Lyman G. H., Khorana A. A., Falanga A. et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol: 2007; 25 5490 5505 (Pubitemid 350232226)
15. Mandalà M., Falanga A., Roila F.. ESMO Guidelines Working Group Management of venous thromboembolism (VTE) in cancer patients. Ann Oncol: 2011; 22 06 vi85 92
16. Maraveyas A., Waters J., Roy R. et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer: 2012; 48 1283 1292
17. Menapace L. A., Peterson D. R., Berry A. et al. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost: 2011; 106 371 378
18. Pabinger I., Alt-Epping B., Demarmels Biasutti F. et al. Venous thrombembolism in tumour patients. Hämostaseologie: 2011; 31 281 290
19. Rasmussen M. S., Jorgensen L. N., Wille-Jorgensen P. et al. FAME Investigators Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery. J Thromb Haemost: 2006; 4 2384 2390 (Pubitemid 44575433)
20. Riess H., Pelzer U., Opitz B. et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. J Clin Oncol: 2010; 28 01 Abstr 4033
21. Riess H., Pelzer U., Hilbig A. et al. Rationale and design of PROSPECT-CONKO 004. BMC Cancer: 2008; 8 361
22. Samama M. M., Cohen A. T., Darmon J. Y. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely Ill medical patients. N Engl J Med: 1999; 341 793 800 (Pubitemid 29420474)
23. Sgouros J., Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. Acta Oncol: 2008; 47 337 346
24. Shaib W., Deng Y., Zilterman D. et al. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res: 2010; 30 10 4261 4264
25. Thaler J., Ay C., Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thrombosis and Haemostasis: 2012; 108 1042 1048